Key Highlights: Implications: Wegovy’s new MASH indication turns semaglutide into a dual liver–weight disease asset in India, opening a large, under-treated fatty liver market (about two i...
Key Highlights: Implications: Qdenga’s approval as India’s first dengue vaccine creates a new prevention market in a country where reported cases have risen about 11‑fold in two decad...
Key Highlights: Implications: Poviztra’s new MASH label lets Emcure plug innovator semaglutide directly into India’s emerging fatty liver treatment market, riding on ESSENCE data (63% stea...
Recent Regulatory Developments India’s biopharmaceutical industry stands at an inflection point where its scientific capabilities and production scale are increasingly recognized globa...
Latest Developments in USFDA Inspections India plays a crucial role in the global pharmaceutical supply chain, supplying a large share of generic medicines to markets around the world. As Indian...
Key Highlights: Implications: Nubeqa’s India approval intensifies mHSPC competition against Janssen’s Erleada, amid prostate therapeutics market growing at 8.2% CAGR to $739M by 2030. ...
